Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The biology is compelling enough to justify that careful engagement
10.1176/ajp.2006.163.11.1905 75
It is a growth hormone-releasing peptide and ghrelin mimetic
6 Challenges for clinical use of IGF-1R-silencing agents 6.1 Toxicity of IGF-1R antagonists Clinical trials of a large number IGF-1/2, IGF-1R, IRS-1, PI3K and mTOR antagonists have been abandoned due to limited anti-cancer activity, or to the toxicity of these agents (41, 53), further supporting the need to continue studies on LL6 and other molecules that are well tolerated in mice and effective at doses that are not toxic to normal cells (54)
When combined with professional medical evaluation, genetic insights and biomarker context empower more informed discussions about medication safety, dosing thresholds, and whether alternative pain management strategies align with your individual health profile
